HPMPC therapy of MCMV-induced retinal disease in the SCID mouse measured by electroretinography, a non-invasive technique

• Published in: Antiviral research 2003-08, Vol.59 (3), p.193-200
• Main Authors: Garneau, Michel, Bolger, Gordon T., Bousquet, Christiane, Kibler, Philip, Tremblay, François, Cordingley, Michael G.
• Format: Article
• Language: English
• Subjects: Animals; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiviral agents; Antiviral Agents - administration & dosage; Antiviral Agents - therapeutic use; Biological and medical sciences; Cidofovir; Cytomegalovirus; Cytomegalovirus Retinitis - drug therapy; Cytomegalovirus Retinitis - virology; Cytosine - administration & dosage; Cytosine - analogs & derivatives; Cytosine - therapeutic use; Disease Models, Animal; Electroretinography; Electroretinography - methods; Eye Infections, Viral - drug therapy; Eye Infections, Viral - virology; Female; Herpesviridae Infections - drug therapy; Herpesviridae Infections - virology; Humans; Medical sciences; Mice; Mice, SCID; Muromegalovirus - pathogenicity; Organophosphonates; Organophosphorus Compounds - administration & dosage; Organophosphorus Compounds - therapeutic use; Pharmacology. Drug treatments; Retina - virology; Retinal disease; SCID mouse; Treatment Outcome; Virus Replication
• ISSN: 0166-3542; 1872-9096
• DOI: 10.1016/S0166-3542(03)00112-8

The purpose of these studies was to investigate the use of non-invasive electroretinography for the evaluation of retinal disease and its treatment in an ocular murine cytomegalovirus (MCMV) disease model. While under anesthesia, 10 2.6 plaque forming units (pfu) of salivary gland passaged, Smith strain MCMV was injected in the anterior chamber of 6- to 8-week-old severe combined immunodeficiency (SCID) mice. At various times post-inoculation, bright-flash scotopic electroretinogram, viral titer, and histology were obtained from the injected eye. Antiviral therapy was tested using 0.1 and 5 mg/kg/day subcutaneous injections of HPMPC (Cidofovir) once daily for 5 consecutive days. In infected animals, the a- and b-waves of the electroretinographic (ERG) signal were significantly reduced as of 10 days post-inoculation when compared to control animals. Therapy with HPMPC 0.1 mg/kg/day subcutaneously (s.c.) once daily for 5 consecutive days was able to delay the decrease in ERG wave amplitude and inhibit viral replication, whereas 5 mg/kg/day s.c. significantly protected the ERG, completely inhibited viral replication, and maintained ocular viral titer below the limit of detection for up to 17 days post-infection. The reduction of ERG activity during progression of retinal disease correlated well with reduction of disease pathology. ERG recording represents a valuable non-invasive technique to measure the progression of the retinal disease induced by MCMV and the efficacy of antiviral treatment in the ocular MCMV disease model.